Brunner Lab

Publications

Rypdal, V; Brunner, HI; Feldman, BM; Ruperto, N; Aggarwal, A; Angeles-Han, ST; Backström, M; Balay-Dustrude, E; Bracaglia, C; De Benedetti, F; Vojinovic, J; Weiss, PF; Gottlieb, B; Consolaro, A. Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force. Annals of the Rheumatic Diseases. 2025; 84:1425-1436.

De Lisa, R; de Andres-Trelles, F; Bax, R; Galluzzo, S; Alward, B; Thomson, A; Karres, D; Brunner, HI; Ruperto, N; Egger, GF. New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on paediatric drug development. Frontiers in Medicine. 2025; 12:1583140.

Zhao, J; Zhao, X; Mizuno, T; Irie, K; Devarajan, P; Brunner, HI; Setchell, KD R. Volumetric Absorptive Microsampling Combined with Mass Spectrometry to Support Pharmacokinetically-Guided Precision Dosing of Mycophenolate Mofetil in Pediatric Lupus Nephritis Patients. The journal of applied laboratory medicine. 2025; 10:806-819.

Cody, EM; Sproles, A; Rose, J; Huang, B; Devarajan, P; Brunner, HI; Thornton, S. Development and Validation of Multiplex Assays for Lupus Nephritis Activity Biomarkers. Kidney International Reports. 2025; 10:2255-2264.

Ohnishi, T; Wilkerson, J; Bayat, N; Farhadi, PN; Faiq, A; Dillon, CF; Schiffenbauer, A; Parks, CG; Brunner, HI; Goldberg, B; Miller, FW; Rider, LG. Infections preceding diagnosis associated with myositis phenotypes in a national patient registry. Clinical and Experimental Rheumatology. 2025; 43:1204-1212.

Arnaud, L; Ruiz-Irastorza, G; Aranow, C; Bernatsky, S; Dall'Era, M; Adelowo, O; Bae, SC; Beretta, L; Bonfa, E; Cervera, R; Svenungsson, E; Tamirou, F; Tegzová, D; Tektonidou, MG. ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. The Lancet. Rheumatology. 2025; 7:e505-e518.

Ruperto, N; Li, C; Chinniah, K; Uziel, Y; Synoverska, O; Sawhney, S; Calvo, I; Louw, I; Lu, M; Patel, PN; Koch, GG; Martini, A; Lovell, DJ; Brunner, H. OP0212 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases. 2025; 84:176-177.

Kasap-Cuceoglu, M; Huggins, J; Ting, T; Smith-Rodriguez, J; Merritt, A; Brunner, H. POS1172 EVALUATING THE STANDARDIZED STEROID REGIMEN (SSR) FOR CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: RETROSPECTIVE INSIGHTS FROM REAL-WORLD DATA. Annals of the Rheumatic Diseases. 2025; 84:1242-1243.

Pons Estel, GJ; Quintana, R; Nieto, R; Brunner, H; Scolnik, M; Funes Soaje, C; Alba, P; Saurit, V; García, MA; Berbotto, G; Zazzetti, F; Orillion, A; Sbarigia, U; Pons-Estel, B. POS0841 THE RENAL ACTIVITY INDEX FOR LUPUS IDENTIFIES AND PREDICTS COMPLETE RENAL REMISSION OR ABSENCE OF KIDNEY INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 2025; 84:985-986.

DiFrancesco, M; Wilson, E; Brunner, H. POS1400 PERIVENTRICULAR ABNORMALITY GRADIENTS OF RELAXOMETRY AND SUSCEPTIBILITY METRICS BY NEUROIMAGING: COMPARING LUPUS AND MULTIPLE SCLEROSIS. Annals of the Rheumatic Diseases. 2025; 84:1421-1422.

Vega-Fernandez, P; Huggins, J; Angeles-Han, S; Lovell, DJ; Brunner, H; Rogers, K; Quinlan-Waters, M; Thornton, S; Cassedy, A; Ting, T. POS0295 RELATIONSHIP AMONG A PEDIATRIC-SPECIFIC ULTRASOUND SCORING SYSTEM FOR THE EVALUATION OF ARTHRITIS AND BIOLOGIC MARKERS OF INFLAMMATION. Annals of the Rheumatic Diseases. 2025; 84:556.

Barraclough, M; Mckie, S; Rittner, L; Knight, A; Katz, P; Hanly, J; Legge, A; Mackay, M; Dobrowolski, C; Brunner, H; Parker, B; Bruce, I; Touma, Z; Appenzeller, S. INTERNATIONAL EFFORT IN HARMONIZING COGNITIVE IMPAIRMENT RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS. The Journal of rheumatology. 2025; 52:39-40.

DiFrancesco, M; Brunner, H. VOLUME AND DYNAMIC BLOOD FLOW OF THE CHOROID PLEXUS IN NEUROINFLAMMATORY DISEASE. The Journal of rheumatology. 2025; 52:106-107.

Connelly, K; Koelmeyer, R; Ayton, D; May, J; Gregory, K; Eades, LE; Barallon, R; Kandane-Rathnayake, R; Golder, V; Anzum, A; Furie, RA; van Vollenhoven, RF; Banerjee, S; Morand, E. Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study. Lupus Science and Medicine. 2025; 12:e001484.

Macaraeg, M; Baker, E; Handorf, E; Matt, M; Brunner, H; Grom, AA; Henrickson, M; Huggins, J; Zhang, W; Lee, P; Marsh, R; Schulert, GS. Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Arthritis and Rheumatology. 2025; 77:596-605.

Maccora, I; Altaye, M; Greis, KD; Brunner, HI; Duell, A; Haffey, WD; Nguyen, T; Quinlan-Waters, M; Schulert, GS; Sproles, A; Utz, VM; Thornton, S; Angeles-Han, ST. Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation (Informa). 2025; 33:603-612.

Brunner, HI; Shmagel, A; Horneff, G; Foeldvari, I; Antón, J; Ramanan, AV; Qian, Y; Unnebrink, K; Hao, S; Camp, HS; Khan, N; Liu, W; Mohamed, ME F. Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial. Arthritis Care and Research. 2025; 77:584-593.

Shishov, M; Weiss, PF; Levy, DM; Chang, JC; Angeles-Han, ST; Ogbu, EA; Nanda, K; Sherrard, TM; Goldmuntz, E; Lovell, DJ; Rider, LG; Brunner, HI. 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges. Arthritis Care and Research. 2025; 77:573-583.

Eloseily, E; Pickering, A; Dhakal, S; Ruperto, N; Brunner, HI; Grom, AA; Thornton, S. Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction. Arthritis Care and Research. 2025; 77:513-521.

Hamdi, W; Migowa, A; Ferjani, HL; Makhloufi, CD; Makhlouf, Y; Nasef, SI; Ziade, N; Baraliakos, X; Brunner, H; Hassan, M; Furia, FF; Slimani, S; Scott, C; Hadef, D. Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis. Clinical Rheumatology. 2025; 44:901-922.

Li, Y; Huang, B; Andorf, S; Yue, X; Lovell, DJ; Brunner, HI. Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials. ACR Open Rheumatology. 2025; 7:e11788.

Sadun, RE; Cooper, JC; Belot, A; Avcin, T; Aggarwal, A; Ainsworth, J; Akinsete, A; Ardoin, SP; Beresford, MW; Bortey, L; Woodside, A; Lewandowski, LB; Smith, EM; CARRA SLE Committee and PReS Lupus Working Party, . Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research. Annals of the Rheumatic Diseases. 2025; 84:158-168.

Ogbu, EA; Brunner, HI; Imundo, L. Systemic lupus erythematosus in childhood and adolescence. Dubois Lupus Erythematosus and Related Syndromes. : Elsevier; Elsevier; 2025.

Ogbu, EA; Sagcal-Gironella, AC P; Eberhard, BA; Huggins, JM; Klein-Gitelman, MS; Onel, K; Chen, C; Huang, B; Brunner, HI. Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale. ACR Open Rheumatology. 2025; 7:e11737.

Soulsby, WD; Olveda, R; He, J; Berbert, L; Weller, E; Barbour, KE; Greenlund, KJ; Schanberg, LE; von Scheven, E; Hersh, A; Dean, J; DeCoste, C; Dedeoglu, F; DeGuzman, M. Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study. Arthritis Care and Research. 2025; 77:38-49.

Maccora, I; Brunner, HI; Cassedy, A; Altaye, M; Quinlan-Waters, M; Lovell, DJ; Grom, A; Angeles-Han, ST. Achieving Medication-Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 2025; 7:e11751.

Randell, RL; Schanberg, LE; Beard, C; Phillips, T; Hornik, CP; Cohen-Wolkowiez, M; Balevic, SJ; Rubinstein, T; Vasquez, N; Wahezi, D; Fennell, J; Jiang, Y; Rodgers, L; Swaffar, C. Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial. ACR Open Rheumatology. 2025; 7:e11780.

Parks, CG; Wilkerson, J; Rose, KM; Faiq, A; Farhadi, PN; Bayat, N; Schiffenbauer, A; Brunner, HI; Goldberg, B; Sandler, DP; Miller, FW; Rider, LG. Occupational and Hobby Exposures Associated With Myositis Phenotypes in a National Myositis Patient Registry. Arthritis Care and Research. 2025; 77:104-115.

Chang, MH; Barbar-Smiley, F; Akoghlanian, S; Drew, J; Angeles-Han, ST; Quinlan-Waters, M; Bohnsack, JF; Cooper, AM; Edelheit, B; Twachtman-Bassett, J; Stern, S; Sterba Rakovchik, Y; Stephens, A; Steigerwald, K. Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology Online Journal. 2024; 22:88.

Brunner, HI; Schulert, GS; Sproles, A; Thornton, S; Cornejo, GV; Antón, J; Cuttica, R; Henrickson, M; Foeldvari, I; Kingsbury, DJ; Lovell, DJ; Martini, A; Ruperto, N; Grom, AA. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.

Ogbu, EA; Brunner, HI; Eloseily, E; Aviel, YB; Nanda, K; Schmeling, H; Tory, H; Uziel, Y; Viola, DO; Wahezi, DM; Ruperto, N; Huang, B; Grom, A; Thornton, S. Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1723-1732.

Vega-Fernandez, P; Rogers, K; Avar-Aydin, PO; Quinlan-Waters, M; Huggins, J; Brunner, HI; Lovell, DJ; Altaye, M; Cassedy, A; Meyers, AB; Ting, TV. Validation of the ankle-specific pediatric arthritis ultrasound scoring system in children with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2024; 69:152545.

Saper, VE; Tian, L; Verstegen, RH J; Conrad, CK; Cidon, M; Hopper, RK; Kuo, CS; Osoegawa, K; Baszis, K; Bingham, CA; Ambler, W; Amoruso, M; Angeles-Han, S; Ardoin, S. Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:2996-3013.e7.

Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Alexeeva, E; Appenzeller, S; Chasnyk, V; Griffin, T; Suarez, CN; Knupp-Oliveira, S; Spindler, A; Terreri, MT; Viola, DO; Xavier, RM. Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. The Journal of rheumatology. 2024; 51:1125-1134.

Brunner, HI; Akikusa, JD; Al-Abadi, E; Bohnsack, JF; Boteanu, AL; Chedeville, G; Cuttica, R; De La Pena, W; Jung, L; Kasapcopur, O; Liu, S; Martini, A; Lovell, DJ; Ruperto, N. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83:1561-1571.

Huang, B; Kouril, M; Chen, C; Daraiseh, NM; Ferraro, K; Mannion, ML; Brunner, HI; Lovell, DJ; Morgan, EM. Digital health technology to support patient-centered shared decision making at point of care for juvenile idiopathic arthritis. Frontiers in Pediatrics. 2024; 12:1457538.

Brunner, HI; Ruperto, N; Ramanan, AV; Horneff, G; Minden, K; Calvo Penades, I; Alexeeva, E; Cleary, G; Stern, SM; Kone-Paut, I; Wagner-Weiner, L; Stern, S; Zeft, A; Dare, J. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology. 2024; 63:2535-2546.

Cody, E; Brunner, HI. Renal disease in pediatric rheumatology. Current Opinion in Rheumatology. 2024; 36:322-327.

Lovell, DJ; Tzaribachev, N; Henrickson, M; Simonini, G; Griffin, TA; Alexeeva, E; Bohnsack, JF; Zeft, A; Horneff, G; Vehe, RK; Costanzo, D; Rennebohm, R; Waugaman, B; Brodus, E. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.

Avar-Aydın, PÖ; Brunner, HI. Revisiting Childhood-Onset Systemic Lupus Erythematosus. Turkish Archives of Pediatrics. 2024; 59:336-344.

Mannion, ML; Amin, S; Balevic, S; Chang, ML; Correll, CK; Kearsley-Fleet, L; Hyrich, KL; Beukelman, T. Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1090-1098.

Connelly, K; Koelmeyer, R; Ayton, D; May, J; Gregory, K; Eades, L; Barallon, R; Kandane-Rathnayake, R; Golder, V; Anzum, A; Furie, RA; Van Vollenhoven, RF; Banerjee, S; Morand, E. AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY. Annals of the Rheumatic Diseases. 2024; 83:1805-1807.

Peng, J; Dönnes, P; Ardoin, SP; Schanberg, LE; Lewandowski, L; Ardoin, S; Dewitt, EM; Rabinovich, CE; Ellis, J; Mieszkalski, K; Paepke-Tollefsrud, DE; Robinson, G; Jury, EC; Ciurtin, C. Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature. Arthritis and Rheumatology. 2024; 76:455-468.

Sinha, R; De Benedetti, F; Grom, AA. Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022. Pediatric Rheumatology Online Journal. 2024; 21:91.

de Benedetti, F; Grom, AA; Brunner, H. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.

Sagcal-Gironella, AC P; Merritt, A; Mizuno, T; Dharnidharka, VR; McDonald, J; DeGuzman, M; Wahezi, D; Goilav, B; Onel, K; Kim, S; Hersh, A; Huang, B; Devarajan, P; Brunner, H. Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study). Journal of Clinical Trials. 2024; 14:563.

Brucia, RC; Hayward, K; Brunner, HI; Lopez-Pena, M; Shenoi, S; Soybilgic, A; Nocton, JJ. Practice Analysis and Determining the Knowledge and Skills Expected of a Pediatric Rheumatologist. ACR Open Rheumatology. 2023; 5:619-623.

Woo, JM P; Simmonds, F; Dennos, A; Son, MB F; Lewandowski, LB; Rubinstein, TB. Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:2285-2294.

Ruperto, N; Lovell, DJ; Berman, A; Anton, J; Viola, DO; Lauwerys, B; Rama, ME; Bohnsack, J; Breedt, J; Fischbach, M; Wong, R; Askelson, M; Martini, A; Brunner, HI. Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials. The Journal of rheumatology. 2023; 50:1471-1480.

Brunner, HI; Tzaribachev, N; Louw, I; Calvo Penades, I; Avila-Zapata, F; Horneff, G; Foeldvari, I; Kingsbury, DJ; Paz Gastanaga, ME; Wouters, C; Zhuo, J; Martini, A; Lovell, DJ; Ruperto, N. Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care and Research. 2023; 75:2259-2266.

Schanberg, LE; Mulugeta, L; Akinlade, B; Brunner, HI; Chen, J; Colbert, RA; Delgaizo, V; Gastonguay, MR; Glaser, R; Imundo, L; Singh, R; Sinha, V; Yancey, CL; Yao, L. Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design. Arthritis and Rheumatology. 2023; 75:1856-1866.

Connelly, K; Eades, LE; Koelmeyer, R; Ayton, D; Golder, V; Kandane-Rathnayake, R; Gregory, K; Brunner, H; Burke, L; Arnaud, L; Roy, S; Kafka, S; Morel, T; Pincus, Y. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nature reviews. Rheumatology. 2023; 19:592-602.

Ramanan, AV; Quartier, P; Okamoto, N; Foeldvari, I; Spindler, A; Fingerhutová, S; Antón, J; Wang, Z; Meszaros, G; Araújo, J; Kasapcopur, O; Unsal, E; Vaidyanathan Ramanan, A; Lacassagne, S. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. The Lancet. 2023; 402:555-570.

Cody, EM; Wenderfer, SE; Sullivan, KE; Kim, AH J; Figg, W; Ghumman, H; Qiu, T; Huang, B; Devarajan, P; Brunner, HI. Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatric Nephrology. 2023; 38:2679-2688.

Ruperto, N; Lovell, DJ; Berman, A; Ávila-Zapata, F; Horneff, G; Alessio, M; Becker, ML; Belot, A; Burgos-Vargas, R; Gamir, ML; Askelson, M; Wong, R; Martini, A; Brunner, HI. Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study. Arthritis Care and Research. 2023; 75:1804-1814.

Roberts, JE; Williams, K; Dallas, J; Eckert, M; Huie, L; Smitherman, E; Soulsby, WD; Zhao, Y; Son, MB F; Abel, N; Delnay, N; Dempsey, V; DeSantis, E; Dickson, T. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. The Journal of rheumatology. 2023; 50:1047-1057.

Brunner, HI; Vadhariya, A; Dickson, C; Crandall, W; Kar-Chan Choong, C; Birt, JA; Ruperto, N; Ramanan, AV. Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Science and Medicine. 2023; 10:e000817.

Smitherman, EA; Chahine, RA; Beukelman, T; Lewandowski, LB; Rahman, AK M F; Wenderfer, SE; Curtis, JR; Hersh, AO; Abel, N; Abulaban, K; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75:1553-1562.

Hawtin, S; André, C; Collignon Zipfel, G; Appenzeller, S; Bannert, B; Baumgartner, L; Beck, D; Betschart, C; Boulay, T; Brunner, H; Siegel, R; Gergely, P; Shisha, T; Junt, T. POS1140 A NOVEL TLR7/8 ANTAGONIST BLOCKS PRO-INFLAMMATORY FUNCTION OF IMMUNE COMPLEXES FROM LUPUS PATIENTS AND ABROGATES LUPUS-LIKE DISEASE IN MICE. Annals of the Rheumatic Diseases. 2023; 82:899.

Ruperto, N; Foeldvari, I; Alexeeva, E; Aktay Ayaz, N; Schulert, G; Özen, S; Popov, A; Ramanan, A; Scott, C; Sozeri, B; Pricop, L; Lovell, DJ; Martini, A; Brunner, H. POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL. Annals of the Rheumatic Diseases. 2023; 82:379-380.

Cody, EM; Wilson, BE; Ogbu, EA; Huggins, JL; Chen, C; Qiu, T; Ting, TV; Flores, F; Huang, B; Brunner, HI. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Science and Medicine. 2023; 10:e000884.

Hawtin, S; André, C; Collignon-Zipfel, G; Appenzeller, S; Bannert, B; Baumgartner, L; Beck, D; Betschart, C; Boulay, T; Brunner, HI; Siegel, R; Gergely, P; Shisha, T; Junt, T. Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy. Cell Reports Medicine. 2023; 4:101036.

Stotter, BR; Cody, E; Gu, H; Daga, A; Greenbaum, LA; Duong, MD; Mazo, A; Goilav, B; Boneparth, A; Kallash, M; Levy, DM; Brunner, HI; Verghese, PS; Wenderfer, SE. Acute kidney injury requiring kidney replacement therapy in childhood lupus nephritis: a cohort study of the Pediatric Nephrology Research Consortium and Childhood Arthritis and Rheumatology Research Alliance. Pediatric Nephrology. 2023; 38:1653-1665.

Johnson, SR; Gladman, DD; Brunner, HI; Isenberg, D; Clarke, AE; Barber, MR W; Arnaud, L; Fortin, PR; Mosca, M; Voskuyl, AE; Waldhauser, H; Wallace, DJ; Zoma, A; Bruce, IN. Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research. 2023; 75:998-1006.

Ringold, S; Dennos, AC; Kimura, Y; Beukelman, T; Shrader, P; Phillips, TA; Kohlheim, M; Schanberg, LE; Yeung, RS M; Horton, DB; Dean, J; Dedeoglu, F; DeGuzman, M; Delnay, N. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:715-723.

Shiff, NJ; Shrader, P; Correll, CK; Dennos, A; Phillips, T; Beukelman, T; Abel, N; Abulaban, K; Adams, A; Adams, M; Donaldson, B; Dorsey, E; Dover, S; Dowling, J. Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62:804-814.

Borgia, RE; Gurka, MJ; Filipp, SL; Elder, M; Cardel, M; Shiff, NJ; Abel, N; Abulaban, K; Adams, A; Adams, M; Dickson, T; Dingle, J; Donaldson, B; Dorsey, E. Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.

Smitherman, EA; Chahine, RA; Bitencourt, N; Rahman, AK M F; Lawson, EF; Chang, JC; Abel, N; Abulaban, K; Adams, A; Adams, M; Dickson, T; Dingle, J; Donaldson, B; Dorsey, E. Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2023; 50:98-106.

Brunner, HI; Foeldvari, I; Alexeeva, E; Ayaz, NA; Calvo Penades, I; Kasapcopur, O; Chasnyk, VG; Hufnagel, M; Zuber, Z; Schulert, G; Pricop, L; Martini, A; Lovell, D; Ruperto, N. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.

Petri, M; Aringer, M; Ayoub, I; Almaani, S; Brunner, H; Dall’Era, M; Jiang, M; Furie, R; Greco, J; Goldblatt, F; Rovin, B; Wallace, D; Zhang, X; Zhao, L. Systemic Lupus Erythematosus. A Clinician's Pearls & Myths in Rheumatology. : Springer Nature; Springer Nature; 2023.

Soulsby, WD; Balmuri, N; Cooley, V; Gerber, LM; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2022; 20:18.

Neely, J; Ardalan, K; Huber, A; Kim, S; Abel, N; Abulaban, K; Adams, A; Adams, M; Agbayani, R; Aiello, J; Dickson, T; Dingle, J; Donaldson, B; Dorsey, E. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology Online Journal. 2022; 20:50.

Martini, A; Lovell, DJ; Albani, S; Brunner, HI; Hyrich, KL; Thompson, SD; Ruperto, N. Juvenile idiopathic arthritis. In: Donnelly LF, Ed. Diagnostic imaging. Pediatrics. Salt Lake City, Utah: Springer Nature; 2022.

Miraldi Utz, V; Angeles-Han, ST; Mwase, N; Cassedy, A; Hennard, T; Lovell, DJ; Lopper, S; Brunner, HI; Dosunmu, EO; Grom, AA; Henrickson, M; Huggins, JL; Sisk, RA; Ting, TV; Kaufman, AH. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.

Hahn, T; Daymont, C; Beukelman, T; Groh, B; Hays, K; Bingham, CA; Scalzi, L; Abel, N; Abulaban, K; Adams, A; Delnay, N; Dempsey, V; DeSantis, E; Dickson, T. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2022; 20:107.

Cody, E; Rose, J; Hopkins, R; Quinlan-Waters, M; Robben, CE; Qiu, T; Huang, B; Devarajan, P; Brunner, H. Stability of Novel Urinary Biomarkers Used for Lupus Nephritis. Journal of the American Society of Nephrology : JASN. 2022; 33:961-962.

de Amorim, JC; Kishimoto, ST; Elorza, CL C; Cavaletti, FA; Marini, R; Silva, CA; Saad-Magalhães, C; Fernandes, PT; Brunner, HI; Appenzeller, S. Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics. Frontiers in Psychology. 2022; 13:945425.

Ogbu, EA; Brunner, HI. Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America. 2022; 48:725-746.

Cody, EM; Rose, JE; Huang, B; Qiu, T; Brunner, HI; Devarajan, P. Stability of novel urinary biomarkers used for lupus nephritis. Frontiers in Pediatrics. 2022; 10:974049.

Weiss, PF; Fuhlbrigge, RC; von Scheven, E; Lovell, DJ; Colbert, RA; Brunner, HI. Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care and Research. 2022; 74:1058-1064.

Gerss, J; Tedy, M; Klein, A; Horneff, G; Miranda-Garcia, M; Kessel, C; Holzinger, D; Stanevica, V; Swart, JF; Cabral, DA; Brunner, HI; Foell, D. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Annals of the Rheumatic Diseases. 2022; 81:990-997.

Ruperto, N; Chertok, E; Dehoorne, J; Horneff, G; Kallinich, T; Louw, I; Compeyrot-Lacassagne, S; Lauwerys, B; Martin, N; Marzan, K; Pricop, L; Martini, A; Lovell, DJ; Brunner, H. OP0221 EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA). Annals of the Rheumatic Diseases. 2022; 81:145-146.

Ramanan, A; Quartier, P; Okamoto, N; Meszaros, G; Araujo, J; Wang, Z; Liao, R; Crowe, B; Zhang, X; Decker, R; Keller, S; Brunner, H; Ruperto, N. LB0002 BARICITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHDRAWAL, EFFICACY AND SAFETY STUDY. Annals of the Rheumatic Diseases. 2022; 81:207-208.

Ruperto, N; Brunner, H; Berman, A; Avila Zapata, F; Horneff, G; Wagner-Weiner, L; Belot, A; Burgos-Vargas, R; Gámir Gámir, ML; Goldenstein-Schainberg, C; Terreri, MT; Askelson, M; Wong, R; Martini, A; Lovell, DJ. POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases. 2022; 81:422-423.

Ruperto, N; Brunner, HI; Posner, HB; Lazariciu, I; Martini, A; Lovell, DJ. Tofacitinib for juvenile idiopathic arthritis - Authors' reply. The Lancet. 2022; 399:1866.

Aljaberi, N; Wenderfer, SE; Mathur, A; Qiu, T; Jose, S; Merritt, A; Rose, J; Devarajan, P; Huang, B; Brunner, H. Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Science and Medicine. 2022; 9:e000631.

Hossain, MM; Wilkerson, J; McGrath, JA; Farhadi, PN; Brokamp, C; Khan, MT F; Goldberg, B; Brunner, HI; Macaluso, M; Miller, FW; Rider, LG. The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine. 2022; 9:842586.

Cody, EM; Brunner, HI. Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America. 2022; 48:271-285.

Chalhoub, NE; Wenderfer, SE; Levy, DM; Rouster-Stevens, K; Aggarwal, A; Savani, SI; Ruth, NM; Arkachaisri, T; Qiu, T; Merritt, A; Hoffmann, S; Hollander, M; Hom, C; Houk, L. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.

Andrade Balbi, V; Artur Silva, C; Nascimento Pedrosa, T; Maria Rodrigues Pereira, R; Maria de Arruda Campos, L; Pires Leon, E; Duarte, N; Melechco Carvalho, V; Gofinet Pasoto, S; Cordeiro do Rosário, D; Kolachinski Brandao, L; I Brunner, H; Bonfá, E; Emi Aikawa, N. Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022; 31:97-104.

Dave, I; Estroff, B; Gergely, T; Rostad, CA; Ponder, LA; McCracken, C; Prahalad, S; Abel, N; Abulaban, K; Adams, A; DeSantis, E; Dickson, T; Dingle, J; Donaldson, B. Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. The Journal of rheumatology. 2021; 48:1856-1862.

Beukelman, T; Lougee, A; Matsouaka, RA; Collier, D; Rumsey, DG; Schenfeld, J; Stryker, S; Twilt, M; Kimura, Y; Abel, N; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2021; 19:131.

Balmuri, N; Soulsby, WD; Cooley, V; Gerber, L; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2021; 19:122.

Ruperto, N; Brunner, HI; Synoverska, O; Ting, TV; Mendoza, CA; Spindler, A; Vyzhga, Y; Marzan, K; Grebenkina, L; Tirosh, I; Rivas-Chacon, R; De La Pena, W; Sagcal-Gironella, AC P; Weiss, JE. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. 2021; 398:1984-1996.

van Vollenhoven, RF; Bertsias, G; Doria, A; Isenberg, D; Morand, E; Petri, MA; Pons-Estel, BA; Rahman, A; Ugarte-Gil, MF; Voskuyl, A; Voss, A; Werth, VP; Zakharhova, E; Aranow, C. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine. 2021; 8:e000538.

Ruperto, N; Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Spindler, AJ; Kingsbury, DJ; Schmeling, H; Borzutzky, A; Cuttica, R; Zeft, A; Griffin, T; De Ranieri, D; Carrasco, R. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4495-4507.

Ruperto, N; Brunner, HI; Ramanan, AV; Horneff, G; Cuttica, R; Henrickson, M; Anton, J; Boteanu, AL; Penades, IC; Minden, K; Mallalieu, NL; Martini, A; Lovell, D; De Benedetti, F. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4568-4580.

Kimura, Y; Schanberg, LE; Tomlinson, GA; Riordan, ME; Dennos, AC; Del Gaizo, V; Murphy, KL; Weiss, PF; Natter, MD; Feldman, BM; Rosolowski, B; Ruth, N; Schikler, K; Sepulveda, A. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.

Schultz, K; Divanovic, A; Towe, C; Miethke, A; Wusik, K; Hammill, A; Brunner, H. Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing. Arthritis Care and Research. 2021; 73:1379-1386.

Ong, MS; Ringold, S; Kimura, Y; Schanberg, LE; Tomlinson, GA; Natter, MD; Abel, N; Abulaban, K; Adams, A; Adams, M; Dempsey, V; DeSantis, E; Dickson, T; Dingle, J. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.

Cody, E; Wenderfer, SE; Ma, Q; Merritt, A; Devarajan, P; Brunner, H. Renal Activity Index in Lupus (RAIL) Score Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis. Journal of the American Society of Nephrology : JASN. 2021; 32:610.

Brunner, HI; Abud-Mendoza, C; Mori, M; Pilkington, CA; Syed, R; Takei, S; Viola, DO; Furie, RA; Navarra, S; Zhang, F; Okily, M; Roth, DA; Quasny, H; Ruperto, N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021; 7:e001747.

Brunner, HI; Chen, C; Bovis, F; De Benedetti, F; Espada, G; Joos, R; Akikusa, J; Chaitow, J; Boteanu, AL; Kimura, Y; Martini, A; Lovell, DJ; Huang, B; Ruperto, N. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2021; 73:1264-1274.

Mannion, ML; Xie, F; Horton, DB; Ringold, S; Correll, CK; Dennos, A; Beukelman, T; Abel, N; Abulaban, K; Adams, A; Dingle, J; Donaldson, B; Dorsey, E; Dover, S. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2021; 48:1322-1329.

Ruperto, N; Brunner, HI; Tzaribachev, N; Vega-Cornejo, G; Louw, I; Cimaz, R; Dare, J; Espada, G; Faugier, E; Ferrandiz, M; Nys, M; Wong, R; Martini, A; Lovell, DJ. Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. The Journal of rheumatology. 2021; 48:1073-1081.

Lovell, DJ; Brunner, HI. Evolution in the Understanding of Pediatric-Onset Axial Spondyloarthritis. Arthritis Care and Research. 2021; 73:921-923.

Rumsey, DG; Lougee, A; Matsouaka, R; Collier, DH; Schanberg, LE; Schenfeld, J; Shiff, NJ; Stoll, ML; Stryker, S; Weiss, PF; Dean, J; Dedeoglu, F; DeGuzman, M; Delnay, N. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.

Cody, EM; Bennett, MR; Gulati, G; Ma, Q; Altaye, M; Devarajan, P; Brunner, HI. Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity. Kidney International Reports. 2021; 6:1949-1960.

Dominguez, D; Kamphuis, S; Beyene, J; Wither, J; Harley, JB; Blanco, I; Vila-Inda, C; Brunner, H; Klein-Gitleman, M; McCurdy, D; Barr, S; Boire, G; Rich, E; Silverman, ED. Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. The Journal of rheumatology. 2021; 48:852-858.

Maller, J; Fox, E; Park, KT; Paul, SS; Baszis, K; Borocco, C; Prahalad, S; Quartier, P; Reinhardt, A; Schonenberg-Meinema, D; Rabinovich, C; Reed, A; Reed, C; Ringold, S. Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. The Journal of rheumatology. 2021; 48:567-574.

Aljaberi, N; Nguyen, K; Strahle, C; Merritt, A; Mathur, A; Brunner, HI. Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. Arthritis Care and Research. 2021; 73:580-585.

Lovell, DJ; Huang, B; Chen, C; Angeles-Han, ST; Simon, TA; Brunner, HI. Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 2021; 7:e001435.

Brunner, HI; Ruperto, N; Zuber, Z; Cuttica, R; Keltsev, V; Xavier, RM; Burgos-Vargas, R; Penades, IC; Silverman, ED; Espada, G; Wells, C; Lovell, DJ; Martini, A; de Benedetti, F. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Arthritis and Rheumatology. 2021; 73:530-541.

Quartier, P; Alexeeva, E; Constantin, T; Chasnyk, V; Wulffraat, N; Palmblad, K; Wouters, C; I. Brunner, H; Marzan, K; Schneider, R; Sevcic, K; Butbul, Y; Brik, R; Helo, M. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. Arthritis and Rheumatology. 2021; 73:336-346.

Avar-Aydin, PO; Schultz, K; Brunner, HI. Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus. Outcome Measures and Metrics in Systemic Lupus Erythematosus. : Springer Nature; Springer Nature; 2021.

Reighard, SD; Krishnamurthy, D; Cevik, H; Ochayon, DE; Ali, A; Seelamneni, H; Brunner, HI; Waggoner, SN. Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. Cytotherapy (Informa). 2021; 23:37-45.